Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial evaluating magrolimab in combination with pembrolizumab for relapsed or refractory classical Hodgkin lymphoma. The st…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma [Phase 1]
A Phase 1 study evaluating radiolabeled monoclonal antibody therapy in combination with chemotherapy before stem cell transplantation for ad…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin [NA]
An ongoing clinical trial investigates proton therapy for Hodgkin lymphoma (PRO-Hodgkin), with recruitment currently ongoing at Uppsala Univ…
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating SL-279252, a PD-1-Fc-OX40L fusion protein, in adults with advanced solid tumors or lymphomas has been completed wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma [Phase 2, Phase 3]
Ongoing Phase 2/Phase 3 clinical trial for relapsed/refractory Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of a conditioning regimen using gemcitabine hydrochloride, clofarabine, and b…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: PTCy and ATG for MSD and MUD Transplants [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating post-transplant cyclophosphamide and anti-thymocyte globulin for matched sibling and matched unr…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) [Phase 1]
Phase 1 trial evaluating LMP-, BARF1-, and EBNA1-specific cytotoxic T cells for EBV-positive lymphomas; Hodgkin and Non-Hodgkin lymphoma inc…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment [Phase 2]
Phase 2 study examining nivolumab plus brentuximab vedotin in patients aged 5-30 with relapsed or refractory classical Hodgkin lymphoma; the…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) [Phase 2]
A Phase 2 study of pembrolizumab (MK-3475) in relapsed or refractory classical Hodgkin lymphoma and relapsed/refractory primary mediastinal …
-
CLINICAL_TRIALS other · 2025-02-04Clinical Trial Update: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation [Phase 3]
A Phase 3 trial evaluating AB-205 in lymphoma patients undergoing autologous hematopoietic cell transplantation was terminated.
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD [Phase 2]
Phase 2 study evaluating salvage BGD chemotherapy with autologous stem cell transplant consolidation in advanced classical Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
This clinical trial investigates the role of spectral CT in evaluating cardiotoxicity from anthracycline therapy in patients with Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluated a four-drug combination (doxorubicin, pembrolizumab, vinblastine, dacarbazine) for classical Hodgkin lymphoma. T…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
This clinical trial update reports on the frequency of pulmonary toxicity in patients treated for Hodgkin lymphoma. It summarizes current sa…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma [Phase 4]
Phase 4 clinical trial update evaluating Brentuximab vedotin for relapsed/refractory Hodgkin lymphoma; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma [NA]
A clinical study evaluating epigenetic and inflammatory markers of accelerated biological aging in patients with Hodgkin lymphoma in remissi…
-
FDA label_change · 2025-01-03FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…
-
CLINICAL_TRIALS other · 2024-12-31Clinical Trial Update: Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial
This clinical trial update describes the use of circulating tumor DNA genotyping to biologically monitor patients in the FIL-Rouge trial for…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma [Phase 1]
Phase 1 trial testing EBV-specific cytotoxic T cells in relapsed EBV-positive lymphomas has completed, assessing safety and preliminary acti…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
A recruiting clinical trial evaluating immunological senescence phenotype as a potential resistance profile to pembrolizumab in relapsed/ref…